Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy - Model, vector, and radionuclide selection Journal Article
| Authors: | Carter, L. M.; Poty, S.; Sharma, S. K.; Lewis, J. S. |
| Article Title: | Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy - Model, vector, and radionuclide selection |
| Abstract: | Intact antibodies and their truncated counterparts (eg, Fab, scFv fragments) are generally exquisitely specific and selective vectors, enabling recognition of individual cancer-associated molecular phenotypes against a complex and dynamic biomolecular background. Complementary alignment of these advantages with unique properties of radionuclides is a defining paradigm in both radioimmunoimaging and radioimmunotherapy, which remain some of the most adept and promising tools for cancer diagnosis and treatment. This review discusses how translational potency can be maximized through rational selection of antibody-nuclide couples for radioimmunoimaging/therapy in preclinical models. Copyright © 2018 John Wiley & Sons, Ltd. |
| Keywords: | animal model; imaging; antibody; therapy; radionuclide |
| Journal Title: | Journal of Labelled Compounds and Radiopharmaceuticals |
| Volume: | 61 |
| Issue: | 9 |
| ISSN: | 0362-4803 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2018-07-01 |
| Start Page: | 611 |
| End Page: | 635 |
| Language: | English |
| DOI: | 10.1002/jlcr.3612 |
| PROVIDER: | scopus |
| PMCID: | PMC6081268 |
| PUBMED: | 29412489 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 4 September 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work